Azenta, Inc. is a leading provider of life sciences solutions, focusing on enabling advancements in research and development through its innovative technologies and services
The company specializes in genomic solutions, including sample storage, processing, and logistics, aimed at supporting biobanking and accelerating the discovery of new therapies. With a commitment to enhancing global health, Azenta's offerings cater to the needs of pharmaceutical and biotechnology companies, academic institutions, and research organizations, ultimately striving to improve the efficiency and effectiveness of life sciences research.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQRGEN) and its peers.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSECRL) and its peers.
Life sciences company Azenta (NASDAQAZTA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, but sales fell by 4.4% year on year to $147.5 million. Its non-GAAP profit of $0.05 per share was in line with analysts’ consensus estimates.
The top nine mid-cap stocks from the last week are: Quantum Computing Inc., BlackBerry Limited, IonQ, Inc., Rigetti Computing, Inc., SoundHound AI, Inc., Xometry, Inc., Lucid Group, Inc., Oklo Inc., and Azenta, Inc.
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
